{
  "timestamp": "20250103_004615",
  "model": "gpt-4o",
  "interaction_type": "direct_answer",
  "question_id": "079eb595",
  "question_text": "Which of the following anti-tubercular drug is avoided in a HIV positive patient on zidovudine, lamivudine and indinavir therapy who develops TB?",
  "messages": [
    {
      "role": "system",
      "content": "You are a medical expert making decisions based on medical knowledge."
    },
    {
      "role": "user",
      "content": "You are a medical expert specializing in the field of Pharmacology.Please help answer this multiple choice question:\n\nQuestion: Which of the following anti-tubercular drug is avoided in a HIV positive patient on zidovudine, lamivudine and indinavir therapy who develops TB?\n\nOptions:\nopa. Pyrazinamide\nopb. Isoniazid\nopc. Ethambutol\nopd. Rifampicin\n\n        ### Output Format\n        Provide your response in valid JSON format:\n        {   \n            \"final_analysis\": \"Your concise analysis following the above structure\",\n            \"answer\": \"Option key from the available options (only key,like opa)\",\n            \"confidence\": Score between 0-100 based on alignment with established medical facts\n        }\n        "
    }
  ],
  "response": "```json\n{\n    \"final_analysis\": \"Rifampicin is known to significantly induce the cytochrome P450 enzyme system, which can lead to decreased plasma levels of protease inhibitors like indinavir. This interaction can reduce the effectiveness of the antiretroviral therapy in HIV-positive patients. Therefore, rifampicin is generally avoided in patients on protease inhibitors such as indinavir.\",\n    \"answer\": \"opd\",\n    \"confidence\": 95\n}\n```",
  "metadata": {
    "topic": "Pharmacology",
    "is_multi_choice": true,
    "has_reasoning_chain": false,
    "has_enhanced_info": false,
    "model_config": "gpt-4o",
    "temperature": 0.0
  }
}